Obesity is a risk factor for asthma, especially nonallergic asthma. Ozone, a common air pollutant, is a nonallergic asthma trigger. Importantly, ozone-induced decrements in lung function are greater in obese and overweight human subjects than in lean individuals. Obese mice also exhibit exaggerated pulmonary responses to ozone. Ozone causes greater increases in pulmonary resistance, in bronchoalveolar lavage neutrophils, and in airway hyperresponsiveness in obese than in lean mice. Our data indicate that IL-33 plays a role in mediating these events. Ozone causes greater release of IL-33 into bronchoalveolar lavage fluid in obese than in lean mice. Furthermore, an antibody blocking the IL-33 receptor, ST2, attenuates ozone-induced airway hyperresponsiveness in obese but not in lean mice. Our data also indicate a complex role for tumor necrosis factor (TNF)-a in obesity-related effects on the response to ozone. In obese mice, genetic deficiency in either TNF-a or TNF-a receptor 2 augments ozone-induced airway hyperresponsiveness, whereas TNF-a receptor 2 deficiency virtually abolishes ozone-induced airway hyperresponsiveness in lean mice. Finally, obesity is known to alter the gut microbiome. In female mice, antibiotics attenuate obesity-related increases in the effect of ozone on airway hyperresponsiveness, possibly by altering microbial production of short-chain fatty acids. Asthma control is often difficult to achieve in obese patients with asthma. Our data suggest that therapeutics directed against IL-33 may ultimately prove effective in these patients. The data also suggest that dietary manipulations and other strategies (prebiotics, probiotics) that alter the microbiome and/or its metabolic products may represent a new frontier for treating asthma in obese individuals.
Obesity is a risk factor for asthma. Both the prevalence and the incidence of asthma are increased in obese individuals (1) (2) (3) . Furthermore, both surgically induced and diet-induced weight loss reduce asthma symptoms in obese patients with asthma (4, 5) . It is increasingly well established that asthma is a highly pleiotropic disease with multiple phenotypes (6) . Even within the subcategory of "obese asthma," at least two different phenotypes exist. One phenotype includes mostly female, nonatopic subjects with late-onset asthma. In this group, obesity appears to be a causative factor for asthma, and weight loss reduces airway hyperresponsiveness (AHR) (5) . The other obese asthma phenotype includes subjects with atopic asthma, usually early-onset. Obesity appears to worsen asthma symptoms in this group of patients with asthma, but it does not appear to cause their asthma: weight loss improves asthma control but does not reduce AHR (5) .
Compared with nonobese patients with asthma, obese patients with asthma do not respond as well to standard asthma control therapeutics (7) (8) (9) . Better understanding of the mechanistic basis for asthma in obese patients is needed for the development of therapeutics that are effective in this population. Such understanding will require appropriate animal models.
Nonatopic asthma is more common in obese than in lean individuals (10) (11) (12) . Furthermore, whereas obesity is a risk factor for asthma, it does not impact other atopic diseases, at least not in adults (13) . Consequently, our research group has been focusing on models in which obese mice are exposed to a nonallergic asthma trigger.
The air pollutant ozone (O 3 ) is one such trigger. O 3 causes asthma symptoms, reduces lung function, and causes AHR (14) (15) (16) . Emergency room visits and hospital admissions for asthma are more common following days of high ambient O 3 (15, 16) . Importantly, O 3 -induced asthma symptoms are greater in obese than in lean children (17) , and O 3 -induced decrements in lung function are greater in obese and overweight adults than in lean adults, especially when those subjects have preexisting AHR (18, 19) .
Obese mice also exhibit exaggerated pulmonary responses to O 3 . O 3 causes increases in pulmonary resistance (R L ) in obese but not in lean mice, and O 3 -induced AHR is greater in obese than in lean mice (20) (21) (22) (23) (24) (25) (26) (27) (Figure 1) . Moreover, obesityrelated increases in the magnitude of O 3 -induced AHR are observed, regardless of the cause of murine obesity. The following mice all have augmented responses to O 3 : obese ob/ob and db/db mice lacking the satiety hormone leptin or its receptor; Cpe fat mice genetically deficient in carboxypeptidase E (Cpe), an enzyme that regulates neuropeptides involved in eating behavior; and mice with diet-induced obesity (28) .
O 3 reacts with lipids in lung and airway lining fluid to generate lipid ozonation products (29) that injure epithelial cells (30) . The ensuing inflammatory response includes increases in bronchoalveolar lavage (BAL) concentrations of acute-phase cytokines and chemokines, such as IL-6, chemokine (C-X-C motif) ligand 1 (CXCL1), tumor necrosis factor (TNF)-a, and IL-33, as well as neutrophil recruitment to the lungs (20, 23, 24, 26, 31) . Compared with lean mice, obese mice have greater increases in these cytokines and chemokines, as well as greater increases in BAL neutrophils (20) (21) (22) (23) (24) (25) (26) (27) 32) (24) . We treated both obese db/db mice and their lean wild-type (WT) controls with either an ST2-blocking or isotype antibody prior to acute O 3 exposure (2 parts per million for 3 h). O 3 -induced increases in BAL IL-33 and neutrophils, in baseline R L , and in the magnitude of AHR were each greater in db/db than in WT mice. In O 3 -exposed db/db mice, anti-ST2 treatment reduced AHR and baseline R L toward, but not to, levels observed in WT mice, whereas anti-ST2 had no effect in WT mice ( Figure 2 ). Anti-ST2 also reduced BAL neutrophils in db/db but not in WT mice. Taken together, the results indicate a role for IL-33 in the augmented responses of obese mice to O 3 .
Exogenous administration of IL-33 promotes airway narrowing, causes AHR, and increases BAL neutrophils by inducing the release of (1) type 2 cytokines such as IL-13 and IL-5; (2) chemokines that use C-X-C motif chemokine receptor 2, such as CXCL1; and (3) IL-6 (45) (46) (47) . Consistent with the greater increases in BAL IL-33 observed in obese than in lean mice after O 3 exposure, we also observed greater increases in BAL IL-13, IL-5, CXCL1, and IL-6 after O 3 exposure in obese than in lean mice (20, 21, 23, 24, 26, 27, 48) . Furthermore, anti-ST2 attenuated but did not abolish O 3 -induced increases in BAL concentrations of each of these cytokines and chemokines in obese mice (24) .
IL-33-dependent increases in IL-13 likely contribute to the ST2-dependent effects of O 3 on baseline R L in obese mice because anti-IL-13 antibodies also attenuate O 3 -induced increases in R L in these mice. IL-33-dependent increases in IL-13 may also contribute to the augmented neutrophil recruitment observed in obese versus lean mice after O 3 exposure because anti-IL-13 also reduces BAL neutrophils in obese O 3 -exposed mice (26) , likely as a result of changes in chemokine (C-C motif) ligand 20. However, IL-33-driven factors other than IL-13 must be responsible for O 3 -induced AHR in obese mice because blocking IL-13 does not attenuate O 3 -induced AHR in obese mice (26) , whereas blocking ST2 does (24) . CXCL1 and IL-6 could be among these factors because BAL CXCL1 and IL-6 are reduced by anti-ST2 treatment in obese O 3 -exposed mice (24) . Furthermore, blocking CXCL1 signaling reduces AHR induced by exogenous IL-33 (46) . IL-6 contributes to allergic airway inflammation in mice (49) , and recent data derived from human patients with asthma suggest a link between serum IL-6 and asthma severity, especially in obese individuals (50) . Effects of IL-33 on CXCL1 and IL-6 may also contribute to the role of IL-33 in neutrophil recruitment because both IL-6 and CXCL1 are required for O 3 -induced increases in BAL neutrophils, including in obese mice (32, 51, 52) . The proposed role of IL-33 is represented schematically in Figure 3 . ) mice, which lack gd T cells, than in obese WT mice (24) . Finally, after O 3 exposure, both airway responsiveness and BAL neutrophils are lower in obese TCRd 2/2 than in obese WT mice (24) . In summary, IL-33 contributes to the augmented responses to O 3 observed in obese mice, at least in part via its ability to induce type 2 cytokine production in ILC2s and gd T cells, though other cellular targets of IL-33, such as airway epithelial cells and macrophages, may also be involved.
Role of TNF-a
Circulating concentrations of TNF-a are elevated in obesity (20, 57) , and data derived from animal models indicate that TNF-a contributes to the etiology of some obesity-related conditions, including insulin resistance (58) (59) (60) (61) (62) . TNF-a may also be relevant for asthma in obesity because obesity confers a greater risk for asthma in subjects with TNF-a polymorphisms that promote TNF-a expression, especially among nonatopic patients with asthma (63) . Exogenous administration of TNF-a can induce AHR (64) , and TNF-a is known to contribute to O 3 -induced AHR in lean mice (65, 66 (26, 27) , as discussed above. Both TNF-a and TNFR2 deficiency attenuated O 3 -induced increases in BAL neutrophils in obese but not in lean mice and effectively abolished obesity-related differences in neutrophil recruitment (26, 27) . The data indicate that TNF-a is required for the augmented effects of acute O 3 exposure on pulmonary inflammatory cell recruitment in obese mice. In contrast, TNF-a and TNFR2 deficiency augmented O 3 -induced AHR in Cpe fat mice, even though deficiencies in TNF-a signaling reduced O 3 -induced AHR in lean control mice (26, 27) . These results indicate that TNF-a protects against O 3 -induced AHR in obese mice. They also emphasize the differing roles of TNF-a in the O 3 responses of lean and obese mice. Finally, these results indicate that O 3 -induced AHR and inflammation are mechanistically dissociated: Neutrophils and/or their products do not contribute to O 3 -induced AHR in obese mice.
Given the importance of IL-33 for O 3 -induced AHR in obese mice (see above), we considered the possibility that TNF-a, acting via TNFR2, might protect obese mice against O 3 -induced AHR by affecting IL-33 expression. We used type 2 cytokine expression to assess the impact of IL-33 in these TNF-a-or TNFR2-deficient mice. BAL IL-13 levels were significantly greater in O 3 -exposed Cpe fat /TNF-a 2/2 than in Cpe fat mice (Figure 4) , and a similar trend was observed in Cpe fat /TNFR2 2/2 versus Cpe fat mice (26, 27) . BAL IL-5 levels were also significantly greater in O 3 -exposed 
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Shore: Obesity, Ozone, and Airway ResponsivenessCpe fat /TNFR2 2/2 than in Cpe fat mice (26) . Taken together with the roles of IL-33 and type 2 cytokines described above, the data are consistent with a role for TNF-a in suppressing IL-33 release and/or suppressing IL-33-dependent effects on target cells in obese mice. How might this effect of TNF-a be mediated? The observation that O 3 -induced increases in BAL protein carbonyls, markers of oxidative stress, were augmented in Cpe fat /TNF-a 2/2 versus Cpe fat mice (26, 27) indicates greater oxidative stress in Cpe fat /TNF-a 2/2 than in Cpe fat mice. Greater oxidative stress would be expected to promote greater epithelial injury, IL-33 release, and subsequent induction of type 2 cytokines, as observed previously (26, 27) . Consequently, it is possible that TNF-a acts to protect against O 3 -induced AHR in obese mice by inducing the expression of antioxidant enzymes. Though TNF-a has the capacity to induce the antioxidants heme oxygenase 1 (Hmox1), metallothionein 1 (Mt1), and metallothionein 2 (Mt2), we were unable to demonstrate a role for TNF-a in the induction of these antioxidants by O 3 in obese mice (26, 27) . However, it is possible that TNF-a contributes to the induction of other antioxidant enzymes, such as the enzyme glutamate-cysteine ligase catalytic subunit that catalyzes the rate-limiting step in the synthesis of the potent antioxidant glutathione.
Role of the Microbiome
An increasing body of evidence supports a role for the microbiome and/or its metabolic products in models of allergic airway disease (40) . A series of preliminary reports from our laboratory suggest that the microbiome also impacts responses to O 3 , including the augmented O 3 -induced AHR of obese mice. Obesity alters the gut microbiome (33) (34) (35) (36) (37) (38) (39) , and there are data indicating a role for the gut microbiome in the insulin resistance and systemic inflammation associated with obesity (33, (67) (68) (69) (70) , as well as in the nonalcoholic fatty liver disease that often accompanies obesity (71) .
We performed a metabolomic profiling experiment in lungs of obese and lean mice exposed to air or O 3 (72) . Many of the identified metabolites were impacted by obesity or O 3 exposure. Among these metabolites were several that are known to require bacteria for their generation. Remarkably, each of these latter metabolites was significantly affected either by obesity, by O 3 , or by the combination of these two factors. These results suggest a role for the microbiome in obesity-related alterations in the response to O 3 . Indeed, in lean mice, we demonstrated that antibiotics attenuated O 3 -induced AHR (73) . Similar results were obtained in obese female mice, in which antibiotics nearly abolished obesity-related differences in O 3 -induced AHR (74) .
In lean mice, treatment with a variety of antibiotics allowed me to identify bacteria taxa that were associated with the magnitude of O 3 -induced AHR. These bacteria were notable plant degraders and producers of short-chain fatty acids (SCFAs). Subsequent analysis of serum indicated reductions in SCFAs only in mice treated with those antibiotics that attenuated responses to O 3 . Furthermore, exogenous administration of SCFAs via the drinking water augmented O 3 -induced AHR in lean mice (75) . Taken together, the data support a role for the microbiome obesity-related increases in the response to O 3 and suggest that microbiota-dependent metabolism of SCFAs may be contributing to this role. Given the importance of genetic factors in affecting the microbiome (76) and reports that TNFR2 deficiency alters gut microbial communities (77) , the data also suggest that the protective role of TNFa/TNFR2 against obesity-related increases in the response to O 3 described above might be mediated via changes in the gut microbiome. Whether obesity-related changes in the microbiome also account for obesity-related differences in the impact of O 3 on the lungs remains to be established.
Conclusions
Our data indicate that IL-33 contributes to the augmented responses to O 3 observed in obese mice, whereas TNF-a exerts a protective effect, at least for O 3 -induced AHR. What are the clinical implications of these observations? Asthma control is often difficult to achieve in obese patients with asthma (78) , and therapeutics that are effective in these patients are desperately needed. Various therapeutics directed against IL-33 are in development and may ultimately prove effective in the treatment of obese patients with asthma. In contrast, the present data suggest that TNF-a inhibitors might actually worsen symptoms in obese patients with asthma. Data supporting a role for the microbiome in this nonallergic model of obese AHR also suggest that dietary manipulations and other strategies (prebiotics, probiotics) that alter the gut microbiome and/or its metabolic products may represent a new frontier for treating asthma in obese individuals. Greater understanding of the bacteria and bacterial products involved, especially in human subjects, is required for the development of such strategies. n 
